Unknown Analyst

[Audio Gap] Praxis, who's going to run through a presentation. Megan?

Megan Sniecinski
Chief Operating Officer

Thank you. Thank you. Good afternoon. I'm Megan Sniecinski, the Chief Operating Officer at Praxis. Building on a remarkable 2025, we've continued executing across our portfolio in our journey to become a commercial company, and we're gaining momentum across all of our 4 late-stage assets.

These are our forward-looking statements. Everything we do at Praxis is -- comes back to one thing, accelerating the delivery of life-altering therapies for patients suffering from CNS disorders, many of whom have been waiting for decades. Looking at our near-term horizon, what's ahead for us this year sets us up well to deliver on this mission.

I want to use our time today to share more about what's happening across each of our programs, what we're excited about and what lies ahead for the company. Our broad pipeline has several near-term catalysts and we're heads down executing to deliver on them. Our ulixa NDA in essential tremor is under review with a PDUFA date late January 2027. And ahead of that, we have our NDA for relutrigine under priority review with a PDUFA date in late September.

At our earnings call last week, we also announced that recruitment was complete for our EMERALD study in broader DEEs with top line results reading out in the fourth quarter of this year. And looking to vormatrigine, we have our POWER1 Phase III study readout this quarter, and we'll be initiating the POWER3 monotherapy study, a milestone this community has been waiting for, using all of the existing exciting features of the vormatrigine profile to deliver on